Immuron (IMRN) Long-Term Deferred Tax (2017 - 2023)
Immuron's quarterly Long-Term Deferred Tax came in at $18660.6 in Q2 2023, up 195.75% year-on-year from $6309.6 in Q2 2022, and up 195.75% quarter-over-quarter from $6309.6 in Q2 2022.
Immuron has reported Long-Term Deferred Tax for 4 years, with the latest figure at $18660.6 in Q2 2023.
- For the quarter ending Q2 2023, Long-Term Deferred Tax rose 195.75% year-over-year to $18660.6; the trailing twelve-month figure through Jun 2023 stood at $18660.6 (up 195.75% YoY), and the FY2023 full-year result was $18660.6, up 195.75% from the prior year.
- Long-Term Deferred Tax for Q2 2023 stood at $18660.6, up from $6309.6 in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $18660.6 in Q2 2023, with the low at $6309.6 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 18,660.62 |
| Jun 30, 2022 | 6,309.61 |
| Jun 30, 2018 | 7.35 Mn |
| Jun 30, 2017 | 6.23 Mn |